Dataset opportunity
Cardiostat — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Cardiostat, usable for Diagnostic AI and Computer Vision.
Score
61.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in medical imaging market = $1.88 billion in 2025, projected to reach $29.95 billion by 2034, exhibiting a CAGR of 36.91% (source: Fortune Business Insights).
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-02
Petal Surgical adds more funding for incisionless surgical robot
therobotreport.com ↗ - 📰press2026-05-29
J&J recalls Impella heart pumps after patient dies
medtechdive.com ↗ - 📰press2026-05-28
Ōura to add blood pressure feature following FDA policy change
medtechdive.com ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Cardiostat holds a highly valuable Medical Imaging Dataset from the healthcare sector, comprising image modality data collected via a medical device. This extensive dataset, supported by API access, substantial data volume, and linked medical records, is exceptionally suitable for developing Diagnostic AI solutions. Its real-world origin and comprehensive nature make it a critical asset for training and validating advanced AI models.
The demand for such data is reflected in the rapidly expanding AI in medical imaging market, which was valued at USD 1.88 billion in 2025 and is projected to reach USD 29.95 billion by 2034, exhibiting a CAGR of 36.91%. Despite the complexities of managing Patient Protected Health Information (PHI) and ensuring regulatory compliance (e.g., HIPAA, GDPR), the proven utility for clinical trials and the specialized medical expertise required for interpreting medical device-generated data formats underscore the dataset's rarity and high business value. ⚠ Diligence (valuable data, access to negotiate): Patient Protected Health Information (PHI) requires strict regulatory compliance (e.g., HIPAA, GDPR).; Data access for clinical trials is already offered, suggesting a structured process but also potential existing agreements.; Data is collected via a medical device, implying specific data formats and potential need for medical expertise for interpretation. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This opportunity presents access to a substantial and clinically validated medical imaging dataset primarily focused on ECG recordings, derived from over 700 global healthcare institutions. With a proven track record of 275,000+ tests and a reported 2 billion annotated beats from 11,000 patients, this data is uniquely positioned to fuel the rapidly expanding AI in medical imaging market. It offers diagnostic-imaging companies and Medical-AI developers the critical, high-quality input needed to train and refine advanced cardiac diagnostic AI models, addressing a significant demand for robust, real-world data.
See dimension details ↓- Dataset Specificity66
dominant 'medical_records', sector healthcare, 1 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume68
3 evidence hits, explicit data-volume mention
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value64
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand97
The global AI in medical imaging market, which heavily relies on medical imaging datasets for training, is projected to grow at a CAGR of 36.91% from 2026 to 2034, reaching USD 29.95 billion by 2034.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 3 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit75
⚠ review — Cardiostat, a product of Icentia, is a medical technology company whose core business involves providing continuous cardiac monitoring services, which includes collecting and analyzing proprietary ECG data to generate reports for healthcare professionals, and they have also publicly released a large Issues: Cardiostat's core business is selling a service that includes the collection of proprietary ECG data and the provision of intelligence through data analysis and; Icentia, the compa
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms the holder's extensive experience in continuous ECG recording and analysis, having completed over 275,000 tests across 700+ global healthcare institutions, providing a rich source of clinically relevant data for diagnostic AI development.
Data-volume signal
This points to an exceptionally large single-lead ECG dataset, comprising 2 billion annotated beats from 11,000 patients, offering an unparalleled volume of cardiac data critical for training sophisticated AI diagnostic models.
API access
This confirms the holder's capability to provide full raw data access and tailored exports, including for clinical trials and arrhythmia analysis, ensuring the flexibility and data utility required by advanced AI development teams.
Coverage
Scanned sources
Deliverable
Premium dataset report
Cardiostat Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in medical imaging market = $1.88 billion in 2025, projected to reach $29.95 billion by 2034, exhibiting a CAGR of 36.91% (source: Fortune Business Insights).. Investment score 61.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.